A model-based strategy was used to inform the early clinical development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor under development for the treatment of hyperlipidemia. The objectives of this model-based approach were to enable bridging variable pharmacokinetic effects, differences among formulations used in development, and to identify an appropriate dose for the phase III confirmatory program.
June 1, 2011
Author(s): Rajesh Krishna, Arthur Bergman, Michelle Green, Marissa Dockendorf, John Wagner, Kevin Dykstra
Year: June 1, 2011